Antengene Corp. Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KYG039571008
HKD
4.50
-0.06 (-1.32%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 6.39%

  • Poor long term growth as Net Sales has grown by an annual rate of % and Operating profit at 0.00% over the last 5 years
  • The company is Net-Debt Free
2

Flat results in Dec 25

3

Risky -

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

HKD 3,058 Million ()

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.74

stock-summary
Return on Equity

15.83%

stock-summary
Price to Book

4.27

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.57%
0%
28.57%
6 Months
3.21%
0%
3.21%
1 Year
15.68%
0%
15.68%
2 Years
341.18%
0%
341.18%
3 Years
103.62%
0%
103.62%
4 Years
-33.53%
0%
-33.53%
5 Years
-72.69%
0%
-72.69%

Antengene Corp. Ltd. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
0.00%
EBIT Growth (5y)
0.00%
EBIT to Interest (avg)
-7.59
Debt to EBITDA (avg)
3.38
Net Debt to Equity (avg)
-0.77
Sales to Capital Employed (avg)
0.69
Tax Ratio
16.11%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
6.39%

Valuation key factors

Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
3.46
EV to EBIT
-21.93
EV to EBITDA
16.48
EV to Capital Employed
10.19
EV to Sales
2.09
PEG Ratio
2.06
Dividend Yield
NA
ROCE (Latest)
-46.45%
ROE (Latest)
13.49%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Antengene Corp. Ltd."
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 14.54% vs 34.01% in Dec 2024",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 25.08% vs 46.11% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "114.20",
          "val2": "99.70",
          "chgp": "14.54%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-236.50",
          "val2": "-366.30",
          "chgp": "35.44%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "2.60",
          "val2": "0.70",
          "chgp": "271.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-259.30",
          "val2": "-346.10",
          "chgp": "25.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,256.60%",
          "val2": "-3,966.70%",
          "chgp": "171.01%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
114.20
99.70
14.54%
Operating Profit (PBDIT) excl Other Income
-236.50
-366.30
35.44%
Interest
2.60
0.70
271.43%
Exceptional Items
0.20
0.10
100.00%
Consolidate Net Profit
-259.30
-346.10
25.08%
Operating Profit Margin (Excl OI)
-2,256.60%
-3,966.70%
171.01%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 14.54% vs 34.01% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 25.08% vs 46.11% in Dec 2024

stock-summaryCompany CV
About Antengene Corp. Ltd. stock-summary
stock-summary
Antengene Corp. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates stock-summary
Icon
No Company Details Available